European Heart and Rhythm Association guidelines on new oral anticoagulants: A bold step forward

Medical science is witnessing a progressive revolution and evolution throughout the globe with continual improvement in diagnostics and therapeutic interventions. The literary and practical updates in medical sciences are highly essential for the betterment of patients well-being. The article “new factor Xa inhibitor” published in the current issue of the journal by Bhanwra and Ahluwalia is a comprehensive review of orally active anticoagulant apixaban. The article definitely adds to our current knowledge about these new revolutionary drugs for the prevention of thrombosis, stroke and other clinical diseases associated coagulation abnormalities. A comprehensive review of new orally active anticoagulants “new orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly” was published in annals of cardiac anesthesia that had emphasized the lack of consideration for drug drug interaction and renal insufficiency which can jeopardize the safe and efficacious use of new oral anticoagulant (NOAC) and make them look bad or ugly. It had also been emphasized that there is a strong need for guidelines on drug drug interaction and renal dosing to promote the safe and more efficacious use of NOACs. European heart and rhythm association (EHRA) have come out with definitive guidelines on the drug drug interaction and renal dosing which is a bold new step forward in promoting the safe and efficacious use of NOACs.